International Society for Human and Animal Mycology (ISHAM)—New Initiatives
Abstract
:1. Present Status
- Lack of awareness of fungal diseases, especially in developing countries where two thirds of the world population lives. A recent survey in seven Asian countries reported a lack of formal training in medical mycology in 37% of clinicians; each clinician handles only 2–4 invasive fungal infections a month due to lack of suspicion and the absence of diagnostic mycology facilities; 80% of patients could not afford appropriate antifungal drugs. Clinicians fail to follow the standard guidelines of management; 34.3% of clinicians noted that they could not treat patients with appropriate antifungals due to the non-availability of the drug in their country [8];
- It is estimated that two million serious fungal infections are present at any time in Latin American countries, 1.7 million serious fungal infections in 15 African countries and more than two million serious fungal infections in eight countries in Southeast Asia [9];
- Certain game changers in fungal disease patterns have been noted over the years. Three important events over the last decade may explain the change in the paradigm of fungal infections.
- An outbreak of cryptococcosis due to Cryptococcus gattii in the temperate climate of Vancouver Island and the North-Western part of the United States of America, although the fungus had been known to be prevalent only in tropical climates. It was postulated that the fungus spread from Brazil to the temperate region by adaptation over the years [10,11,12];
- Candida auris, a fungus which behaves like bacteria. It is a serious threat due to antifungal resistance and rapid spread in healthcare facilities [15].
- The limited number of diagnostic mycology laboratories in developing countries is the most important stumbling block in managing fungal infections;
- ○
- A survey of eight countries in southeast Asia reported availability of non-culture-based diagnostics (beta-glucan, galactomannan, and Histoplasma antigen detection) in less than 25% of the laboratories [20];
- ○
- A similar picture has been noted in Latin American and Caribbean countries in another survey [21];
- ○
- Even in a developed country like the United Kingdom, a laboratory survey reported availability of β-glucan in 5%, galactomannan in 20%, and fungal PCR diagnosis in 6% laboratories only [22];
- Limited recognition of fungal diseases by international authorities is another barrier in the development of mycology;
- ○
- Although after a prolonged advocacy, the World Health Organization (WHO) has agreed to include yeast antifungal resistance surveillance in the Global Antimicrobial Resistance Surveillance System (GLASS), the start of this surveillance is taking a long time due to inadequacies in diagnostic fungal laboratories and the evolving standard of antifungal resistance testing;
- ○
- Mycetoma and chromoblastomycosis have been included in the WHO Neglected Tropical Disease (NTD) list, but many are still waiting to be included, like paracoccidioidomycosis, fungal keratitis and sporotrichosis;
- ○
- Until the worldwide emergence of C. auris infections, fungal diseases were never included in public health challenge listings, though fungal keratitis, resistant dermatophyte infections, sporotrichosis, Candida vaginitis, etc., are major public health problems affecting large numbers of people. This requires concerted advocacy from organisations working in this field, including ISHAM;
- Antifungal drugs—Due to the limited scope of exploiting differences in metabolism between fungi and humans (both eukaryotes), few antifungal classes are in practice to treat human fungal infections. Both intrinsic resistance and emerging acquired resistance in antifungal drugs is further limiting the scope of antifungal management. Aggravating the problem, antifungal drugs are beyond the reach of the majority of the population in developing countries, either due to cost of the drugs or non-availability in certain countries. In a recent multi-centre study from India on mucormycosis, one quarter of the patients could not be treated with appropriate antifungal drugs despite timely diagnosis [23].
2. Targets of Mycology Societies
3. New Activities Initiated by ISHAM
To Achieve the Above Targets ISHAM Initiated the Following Activities
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Fisher, M.C.; Henk, D.A.; Briggs, C.J.; Brownstein, J.S.; Madoff, L.C.; McCraw, S.L.; Gurr, S.J. Emerging fungal threats to animal, plant and ecosystem health. Nature 2012, 484, 186–194. [Google Scholar] [CrossRef]
- Fisher, M.C.; Gurr, S.J.; Cuomo, C.A.; Blehert, D.S.; Jin, H.; Stukenbrock, E.H.; Stajich, J.E.; Kahmann, R.; Boone, C.; Denning, D.W.; et al. Threats posed by the fungal kingdom to humans, wildlife, and agriculture. mBio 2020, 11, e00449-20. [Google Scholar] [CrossRef]
- Brown, G.D.; Denning, D.W.; Gow, N.A.R.; Levitz, S.M.; Netea, M.G.; White, T.C. Hidden killers: Human fungal infections. Sci. Transl. Med. 2012, 165, 165rv13. [Google Scholar] [CrossRef] [Green Version]
- Friedman, D.Z.P.; Schwartz, I.S. Emerging fungal infections: New patterns and new pathogens. J. Fungi (Basel) 2019, 5, 67. [Google Scholar] [CrossRef] [Green Version]
- Chakrabarti, A.; Singh, S. Multi-drug resistant Candida auris: An epidemiological review. Expert Rev. Anti-Infect. Ther. 2020, 18, 551–562. [Google Scholar] [CrossRef]
- Centres for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States; U.S. Department of Health and Human Services: Atlanta, GA, USA, 2019. Available online: https://www.cdc.gov/drugresistance/biggest-threats.html (accessed on 29 May 2020).
- Kathuria, S.; Singh, P.K.; Sharma, C.; Prakash, A.; Masih, A.; Kumar, A.; Meis, J.F.; Chowdhary, A. Multidrug-resistant Candida auris misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J. Clin. Microbiol. 2015, 53, 1823–1830. [Google Scholar]
- Tan, B.H.; Chakrabarti, A.; Patel, A.; Chua, M.M.M.; Sun, P.L.; Liu, Z.; Rotjanapan, P.; Li, R.; Wahyuningsih, R.; Chayakulkeeree, M.; et al. Clinicians’ Challenges in Managing Patients with Invasive Fungal Diseases in Seven Asian Countries: An Asia Fungal Working Group (AFWG) Survey. Int. J. Infect. Dis. 2020, 95, 471–480. [Google Scholar] [CrossRef]
- Global Action Fund for Fungal Infections (GAFFI). Burden of Disease Map. Available online: https://www.gaffi.org/why/burden-of-disease-maps/ (accessed on 9 June 2020).
- MacDougall, L.; Kidd, S.E.; Galanis, E.; Mak, S.; Leslie, M.J.; Cieslak, P.R.; Kronstad, J.W.; Morshed, M.G.; Bartlett, K.H. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the pacific northwest, USA. Emerg. Infect. Dis. 2007, 13, 42–50. [Google Scholar] [CrossRef]
- Hagen, F.; Ceresini, P.C.; Polacheck, I.; Ma, H.; van Nieuwerburgh, F.; Gabaldón, T.; Kagan, S.; Pursall, E.R.; Hoogveld, H.L.; van Iersel, L.J.; et al. Ancient dispersal of the human fungal pathogen Cryptococcus gattii from the Amazon rainforest. PLoS ONE 2013, 8, e71148. [Google Scholar] [CrossRef] [Green Version]
- Roe, C.C.; Bowers, J.; Oltean, H.; DeBess, E.; Dufresne, P.J.; McBurney, S.; Overy, D.P.; Wanke, B.; Lysen, C.; Chiller, T.; et al. Dating the Cryptococcus gattii dispersal to the North American Pacific Northwest. mSphere 2018, 3, e00499-17. [Google Scholar] [CrossRef] [Green Version]
- Schubach, A.O.; Schubach, T.M.; Barros, M.B. Epidemic cat-transmitted sporotrichosis. N. Engl. J. Med. 2005, 353, 1185–1186. [Google Scholar] [CrossRef]
- Queiroz-Telles, F.; Fahal, A.H.; Falci, D.R.; Caceres, D.H.; Chiller, T.; Pasqualotto, A.C. Neglected endemic mycoses. Lancet Infect. Dis. 2017, 17, e367–e377. [Google Scholar] [CrossRef]
- Jeffery-Smith, A.; Taori, S.K.; Schelenz, S.; Jeffery, K.; Johnson, E.M.; Borman, A.; Candida auris Incident Management Team; Manuel, R.; Brown, C.S. Candida auris: A review of the literature. Clin. Micriobiol. Rev. 2017, 31, e00029-17. [Google Scholar] [CrossRef] [Green Version]
- Verma, S.; Madhu, R. The great Indian epidemic of superficial dermatophytosis: An appraisal. Indian J. Dermatol. 2017, 62, 227–236. [Google Scholar]
- Rudramurthy, S.M.; Shankarnarayan, S.A.; Dogra, S.; Shaw, D.; Mushtaq, K.; Paul, R.A.; Narang, T.; Chakrabarti, A. Mutation in the Squalene Epoxidase Gene of Trichophyton interdigitale and Trichophyton rubrum Associated with Allylamine Resistance. Antimicrob. Agents Chemother. 2018, 62, e02522-17. [Google Scholar] [CrossRef] [Green Version]
- Singh, A.; Masih, A.; Khurana, A.; Singh, P.K.; Gupta, M.; Hagen, F.; Meis, J.F.; Chowdhary, A. High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. Mycoses 2018, 61, 477–484. [Google Scholar] [CrossRef]
- Nenoff, P.; Verma, S.B.; Vasani, R.; Burmester, A.; Hipler, U.C.; Wittig, F.; Krüger, C.; Nenoff, K.; Wiegand, C.; Saraswat, A.; et al. The current Indian epidemic of superficial dermatophytosis due to Trichophyton mentagrophytes–a molecular study. Mycoses 2019, 62, 336–356. [Google Scholar] [CrossRef]
- Chindamporn, A.; Chakrabarti, A.; Li, R.; Sun, P.L.; Tan, B.H.; Chua, M.; Wahyuningsih, R.; Patel, A.; Liu, Z.; Chen, Y.C.; et al. Survey of laboratory practices for diagnosis of fungal infection in seven Asian countries: An Asia Fungal Working Group (AFWG) initiative. Med. Mycol. 2018, 56, 416–425. [Google Scholar] [CrossRef]
- Falci, D.R.; Pasqualotto, A.C. Clinical mycology in Latin America and the Caribbean: A snapshot of diagnostic and therapeutic capabilities. Mycoses 2019, 62, 368–373. [Google Scholar] [CrossRef]
- Schelenz, S.; Owens, K.; Guy, R.; Rautemaa-Richardson, R.; Manuel, R.J.; Richardson, M.; Moore, C.; Enoch, D.A.; Micallef, C.; Howard, P.; et al. National mycology laboratory diagnostic capacity for invasive fungal diseases in 2017: Evidence of sub-optimal practice. J. Infect. 2019, 79, 167–173. [Google Scholar] [CrossRef] [PubMed]
- Patel, A.; Kaur, H.; Xess, I.; Michael, J.S.; Savio, J.; Rudramurthy, S.; Singh, R.; Shastri, P.; Umabala, P.; Sardana, R.; et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin. Microbiol. Infect. 2019, 26, 944.e9–944.e15. [Google Scholar] [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chakrabarti, A.; Meis, J.F.; Cornely, O.A. International Society for Human and Animal Mycology (ISHAM)—New Initiatives. J. Fungi 2020, 6, 97. https://doi.org/10.3390/jof6030097
Chakrabarti A, Meis JF, Cornely OA. International Society for Human and Animal Mycology (ISHAM)—New Initiatives. Journal of Fungi. 2020; 6(3):97. https://doi.org/10.3390/jof6030097
Chicago/Turabian StyleChakrabarti, Arunaloke, Jacques F. Meis, and Oliver A. Cornely. 2020. "International Society for Human and Animal Mycology (ISHAM)—New Initiatives" Journal of Fungi 6, no. 3: 97. https://doi.org/10.3390/jof6030097
APA StyleChakrabarti, A., Meis, J. F., & Cornely, O. A. (2020). International Society for Human and Animal Mycology (ISHAM)—New Initiatives. Journal of Fungi, 6(3), 97. https://doi.org/10.3390/jof6030097